文献速递艾滋病与性传播感染

HIV-1 DNA基因型在低或检测不到HIV RNA病毒载量患者中判断抗逆转录病毒耐药性的效用

Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

在大学医院常规就诊、需要更换当前抗逆转录病毒治疗(ART)的HIV-1感染者中,从DNA基因型判断耐药并与既往RNA基因型(第1组)或同日RNA基因型(第2组)比较;DNA耐药信息丢失在第1组为37.8%、第2组为11.1%,多变量分析仅更长的ART持续时间与信息丢失显著相关。

要点

  • DNA基因型与RNA基因型有一定程度一致性,但DNA存在耐药信息丢失。
  • 第1组DNA信息丢失37.8%,第2组11.1%。
  • 多变量分析中仅更长的ART持续时间与信息丢失显著相关。

核心结论

  • 在真实临床环境中,从外周血单核细胞(PBMC)提取DNA进行基因型检测与RNA基因型有一定程度的一致性。
  • DNA中的信息丢失似乎与更长的ART持续时间相吻合。

研究设计与样本

  • 在 routinely seen at a university hospital 的HIV-1感染者中,对需要更换当前ART者从DNA基因型判断抗逆转录病毒耐药,并与既往RNA基因型(第1组)或同日RNA基因型(第2组)比较。
  • 第1组74例、第2组26例;已知HIV-1感染中位持续时间分别为17.4年和14.2年,ART中位持续时间分别为15.3年和13.5年。
  • 定义「耐药总和」为对NRTI、NNRTI和PI中现有耐药药物数量之和;定义「信息丢失」为DNA样本中观察到的耐药总和低于RNA样本。

主要发现

  • 第1组DNA/RNA耐药总和的中位数(范围):NRTI为0(0-6)/1(0-6),NNRTI为0(0-4)/0(0-4),PI为0(0-7)/0(0-8),与第2组相当。
  • DNA信息丢失在第1组为37.8%,第2组为11.1%。
  • 多变量分析中,仅更长的ART持续时间与信息丢失显著相关。
  • 在携带对一种或多种药物耐药的患者中,结果相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the extent to which drug resistance can be evaluated from proviral HIV-1 DNA genotype compared with RNA genotype at different timepoints. PATIENTS AND METHODS: In HIV-1-infected patients routinely seen at a university hospital, who needed to change their current ART, antiretroviral drug resistance was determined from DNA genotype and was compared with past RNA genotype (group 1) or same-day RNA genotype (group 2). A 'resistance sum' was defined as the sum of agents to which resistance was present and was calculated across NRTI, NNRTI and PI. We defined 'loss of information' as when a lower resistance sum was observed in DNA than in RNA samples. RESULTS: Of the 74 and 26 patients included in groups 1 and 2, respectively, most had a long median duration of known HIV-1 infection (17.4 and 14.2 years) and ART (15.3 years and 13.5 years). For group 1, the median (range) resistance sums between DNA/RNA were 0 (0-6)/1 (0-6) for NRTIs, 0 (0-4)/0 (0-4) for NNRTIs and 0 (0-7)/0 (0-8) for PIs, which were comparable with group 2. Loss of information in DNA was substantial for group 1 (37.8%) and less so for group 2 (11.1%). In multivariable analysis, only longer ART duration was significantly associated with loss of information. Results were similar in patients harbouring resistance to one or more agents. CONCLUSIONS: In a real-life setting, genotyping DNA from PBMC has some degree of concordance compared with RNA. Loss of information in DNA would appear to coincide with longer periods of ART.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Boukli N, Boyd A, Collot M, et al. Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads. J Antimicrob Chemother. 2018. PMID: 30137336. doi:10.1093/jac/dky316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。